Fig. 3From: Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapyKaplan‒Meier method comparing overall survival (OS) in r/r MB-NHL between patients who received CAR-T cell therapy (blue; n = 37; mOS = 12.6 months, 95% CI: 3.85-NA months) and those treated without CAR-T cell therapy (red; n = 8). Patients with no survival data were excludedBack to article page